Atlas Capital Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIIB
Atlas Capital Advisors's BIIB Position: Q2 2026 in Review
Atlas Capital Advisors reduced its Biogen (BIIB) stake by 0.95% in Q2 2026, selling an estimated $5.36K and leaving 2,930 shares worth $633K. The position accounts for 0.07% of the portfolio, ranked #240.
Atlas Capital Advisors first reported a position in BIIB in Q1 2018 and has held it in 19 quarters since. The position peaked at $1.36M in Q2 2020. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Atlas Capital Advisors held 2,930 shares of Biogen worth $633K as of Q2 2026.
- Atlas Capital Advisors sold 28 Biogen shares in Q2 2026, an estimated $5.36K.
- Biogen made up 0.07% of Atlas Capital Advisors's portfolio in Q2 2026, its #240 holding.
- Atlas Capital Advisors first reported a position in Biogen in Q1 2018 and has held it in 19 quarters since.
- Atlas Capital Advisors's Biogen position peaked at $1.36M in Q2 2020.
- 1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.